Iron chelators reduce prostaglandins and leukotrienes by inhibiting cyclooxygenase and lipoxygenase: A hypothesis to attenuate PPARγ transcriptional activity in prostate cancer

Key Points

• Iron chelators are shown to inhibit both prostaglandins and leukotrienes production, which is crucial for reducing inflammation.
• Cyclooxygenase and lipoxygenase enzymes are the primary targets affected by the iron chelators, leading to observed changes in the cancer-associated biomolecules.
• The study evaluates the transcriptional activity of PPARγ, providing insights into how iron chelators may influence cancer progression.
• These findings suggest that iron chelation could be a promising therapeutic approach in managing prostate cancer and its related metabolic pathways.